পদ্ধতির তুলনা করুন

	POEM (Patient-Oriented Eczema Measure)	SCORAD Index (SCORing Atopic Dermatitis)	Skindex-29 (স্কিন ডিজিজ কোয়ালিটি অফ লাইফ ইনস্ট্রুমেন্ট)
ক্ষেত্র	ত্বকবিজ্ঞান	ত্বকবিজ্ঞান	ত্বকবিজ্ঞান
পরিবার	Process / pipeline	Process / pipeline	Process / pipeline
উদ্ভবের বছর	2004	1993	1997
প্রবর্তক	Charman CR, Venn AJ, Williams HC	European Task Force on Atopic Dermatitis (ETFAD)	Chren MM, Lasek RJ
ধরন	Self-report	Clinician-rated	Self-report
মৌলিক উৎস	Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519.	Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19.	Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713.
অপর নাম	POEM Score	SCORAD Index	Skindex, Skindex-QoL
সম্পর্কিত	2	3	1
সারসংক্ষেপ	The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.	The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice.	Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.